Results 51 to 60 of about 46,386 (217)

ROLE OF PYRIDOXINE HYDROCHLORIDE IN THE DEVELOPMENT OF TOLERANCE TO THE TOXIC ACTION OF ISONIAZID IN ANIMALS

Туберкулез и болезни лёгких, 2018
The objective of the study: to assess the impact of continuous and course (intermittent) use of pyridoxine hydrochloride in combination with isoniazid on the rate of tolerance development in rats under conditions of a toxicological experiment.Subjects ...
K. I. Usov, T. A. Guskova, G. G. Yushkov
doaj   +1 more source

Rhabdomyolysis due to isoniazid poisoning resulting from the use of intramuscular pyridoxine

The Turkish Journal of Pediatrics, 2013
Isoniazid is an effective antituberculosis drug. Isoniazid poisoning produces a characteristic clinical syndrome that occurs 30 to 120 minutes after ingestion and includes seizures, metabolic acidosis, and in severe cases, coma.
Tuğba Eyüboğlu, Okşan Derinöz
doaj  

Isoniazid potentiates tigecycline to kill methicillin-resistant Staphylococcus aureus

Emerging Microbes and Infections
Therapeutic option for treating methicillin-resistant Staphylococcus aureus (MRSA) infection is urgently required since its resistance to a broad spectrum of currently available antibiotics.
Xuan-wei Chen, Hao-qing Chen, Jia-han Wu, Zhi-han Wang, Yu-Qing Zhou, Si-qi Tian, Bo Peng   +6 more
doaj   +1 more source

Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review [PDF]

Revista da Sociedade Brasileira de Medicina Tropical
Background: The treatment strategy for latent tuberculosis infection is to reduce the number of tuberculosis cases and consequently reduce the transmission of pathogenic bacteria. This study aimed to determine the safety, effectiveness, and adherence of
Bárbara Manuella Cardoso Sodré-Alves, Melina Mafra Toledo, Ivan Ricardo Zimmermann, Wildo Navegantes de Araújo, Noemia Urruth Leão Tavares   +4 more
doaj   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Isoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin N.

PLoS ONE, 2013
Isoniazid represents a first-line anti-tuberculosis medication in prevention and treatment. This prodrug is activated by a mycobacterial catalase-peroxidase enzyme called KatG in Mycobacterium tuberculosis), thereby inhibiting the synthesis of mycolic ...
Paolo Ascenzi, Andrea Coletta, Yu Cao, Viviana Trezza, Loris Leboffe, Gabriella Fanali, Mauro Fasano, Alessandra Pesce, Chiara Ciaccio, Stefano Marini, Massimo Coletta   +10 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Case series: Kikuchi‐Fujimoto disease with diagnostic overlap

Rheumatology &Autoimmunity, EarlyView.
Kikuchi‐Fujimoto disease (KFD) is a rare, self‐limiting necrotizing lymphadenitis that poses significant diagnostic challenges due to its overlap with tuberculosis, systemic lupus erythematosus (SLE), and malignancy. We present four cases highlighting distinct diagnostic complexities: KFD mimicking tuberculosis with concomitant latent TB infection and ...
Ecem Kalemoglu, Ming Zheng, Danny Arias, Andreina M. Paulino, Aisha Niaz, James Devlin, Valentin Marian   +6 more
wiley   +1 more source

Inhibitory Effect of Antituberculosis Drugs on Human Cytochrome P450-Mediated Activities

Journal of Pharmacological Sciences, 2004
The potential for drug-drug interactions mediated by the inhibition of cytochrome P-450 (CYP) were concerned during antituberculosis therapy. However, the information regarding human CYP inhibition by antituberculosis drugs is limited to isoniazid.
Yuki Nishimura, Norimitsu Kurata, Eriko Sakurai, Hajime Yasuhara   +3 more
doaj   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source